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Abstract
Background: Accurate estimates of the burden of antimicrobial resistance (AMR) are needed to establish the
magnitude of this global threat in terms of both health and cost, and to paramaterise cost-effectiveness evaluations
of interventions aiming to tackle the problem. This review aimed to establish the alternative methodologies used in
estimating AMR burden in order to appraise the current evidence base.
Methods: MEDLINE, EMBASE, Scopus, EconLit, PubMed and grey literature were searched. English language studies
evaluating the impact of AMR (from any microbe) on patient, payer/provider and economic burden published
between January 2013 and December 2015 were included. Independent screening of title/abstracts followed by full
texts was performed using pre-specified criteria. A study quality score (from zero to one) was derived using
Newcastle-Ottawa and Philips checklists. Extracted study data were used to compare study method and
resulting burden estimate, according to perspective. Monetary costs were converted into 2013 USD.
Results: Out of 5187 unique retrievals, 214 studies were included. One hundred eighty-seven studies estimated patient
health, 75 studies estimated payer/provider and 11 studies estimated economic burden. 64% of included studies were
single centre. The majority of studies estimating patient or provider/payer burden used regression techniques. 48% of
studies estimating mortality burden found a significant impact from resistance, excess healthcare system costs ranged
from non-significance to $1 billion per year, whilst economic burden ranged from $21,832 per case to over $3 trillion in
GDP loss. Median quality scores (interquartile range) for patient, payer/provider and economic burden studies were 0.67
(0.56-0.67), 0.56 (0.46-0.67) and 0.53 (0.44-0.60) respectively.
Conclusions: This study highlights what methodological assumptions and biases can occur dependent on
chosen outcome and perspective. Currently, there is considerable variability in burden estimates, which can
lead in-turn to inaccurate intervention evaluations and poor policy/investment decisions. Future research
should utilise the recommendations presented in this review.
Trial registration: This systematic review is registered with PROSPERO (PROSPERO CRD42016037510).
Keywords: Antimicrobial resistance, Antibiotic resistance, Burden, Cost
Background
Antimicrobial resistance (AMR) is a cause for global con-
cern due to the current and potential impact on global
population health, costs to healthcare systems and Gross
Domestic Product (GDP), mainly through reduced treat-
ment options [1]. Recent reports suggest that absolute
numbers of infections due to resistant microbes are
increasing globally [2–4]. Estimates of the potential eco-
nomic burden of AMR from recent reports, such as ‘The
Review on Antimicrobial Resistance’ [1], are being utilised
by policy makers to push AMR up the political agenda [5].
However, more precise estimates of AMR burden are
needed to inform policy through health economic models
evaluating interventions attempting to prevent, treat or
stop the spread of resistant infections [6, 7].
In order to establish burden, the perspective being taken
should be defined. The patient perspective refers to
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associated mortality and morbidity (including clinical out-
comes), while the payer perspective can include attributable
costs to the payers of healthcare including insurers or na-
tional payers [6]. The provider perspective estimates the bur-
den to certain providers of healthcare, such as hospitals and
primary care practices [6]. In cases where there is national/
governmental provision and payment of healthcare services,
the provider and payer perspectives may align to be the
same, such as in the case of the National Health Service and
the Department of Health in England [6]. The economic (or
societal) perspective generally includes the potential impact
on the labour force through lost productivity [8, 9], but can
also include the burden on carers and patient out-of-pocket
expenses [10, 11]. AMR may also create burden through
secondary effects, referred to in this review as secondary
burden. Secondary patient burden, and onward effects to
healthcare system or society, occurs when procedures that
utilise antimicrobials to reduce the risk of post-intervention
adverse events (such as surgical procedures utilising prophy-
lactic antibiotics) are performed less frequently due to AMR
increasing the risk of adverse events [12].
The different perspectives of burden produce varying
outcome measures. For example, from a patient perspective
an excess mortality figure may be determined [13], whilst
looking from a payer or provider perspective could produce
an excess cost of hospital treatment in monetary terms
[14], and economic burden could refer to excess GDP
losses for a country [15]. Obtaining estimates for these dif-
ferent outcomes, may require different methodologies, ran-
ging from case-control studies with regression analyses to
complex mathematical and economic models [16, 17].
Past descriptive review articles have discussed the
methods of estimating the burden of AMR [9, 18, 19].
However, since an update in 2012 of a previous system-
atic review [8, 20], there has been no formal systematic
assessment of the methods used in AMR burden estima-
tion, or the variation in resulting outcomes. The 2012
update concluded economic evidence was lacking, and
that over the 21 studies included there were large varia-
tions in the estimates of AMR burden [8]. However,
there been no formal quality assessment of recent AMR
burden evidence across the stated perspectives, which is
needed when discussing study methodology and its limi-
tations. Given the growing media coverage of and policy
interest in AMR over recent years [21, 22], there has
been a corresponding marked increase in the published
evidence on AMR impact. As such, this review aimed to
capture and assess this recent portion of the literature,
by reviewing the evidence published since the review in
2012 by Smith and Coast [8]. This review aimed to cap-
ture both the burden in the sense of the incremental
impact of resistance (in addition to infection) and the
burden of resistant infections among all of the popula-
tion. Therefore this systematic review aimed to address
the following research questions in regards to the human
population, with no limitation on microbe of interest; (i)
what perspectives and resulting methodologies have
been used to estimate AMR burden in the recent pub-
lished literature? (ii) Do AMR burden estimates differ by
perspective and methodology? (iii) What is the quality of
this recent evidence on the burden of AMR?
Methods
This Systematic review is in line with PRISMA guidance,
is registered with PROSPERO (registration number
PROSPERO CRD42016037510) and has a previously
published protocol [23–25].
Search strategy and eligibility criteria
Studies which aimed to quantify the burden of AMR (in
humans) published since the Smith and Coast review in
2012 [8] were of interest, and as such, the search was lim-
ited from January 2013 – December 2015. Ovid ‘Medline &
EMBASE’, Scopus and EconLit were searched utilising a
search string, which employed combinations of the follow-
ing terms; excess, associated, attributable, burden, morbid-
ity, mortality, cost, economic, clinical, global, impact,
outcome, burden, antibiotic, antimicrobial, multi-drug,
microbial-drug, resistan*, gram-positive, gram-negative,
susceptib*,nonsusceptib*, enterococc*, Escherichia, strepto-
cocc*, staphylococc*, klebsiealla, pseudomonas, neisseria,
chlamydia, clostridi*, mycobacteri*. In deviation to the pub-
lished protocol [25], an additional search of PubMed was
conducted for literature published within the stated time
period, whereby titles were searched using the following
string; “(((((mortality[Title]) OR cost[Title]) OR length of
stay[Title]) OR productivity[Title]) AND resistant[Title])
AND infection*[Title]” [26]. The following websites were
also searched for grey literature: Public Health England,
Public Health Wales, Health Protection Scotland, NHS
Health Scotland, Department of Health (UK), Health Pro-
tection Agency, National Institute for Health and Care Ex-
cellence, Centers for Disease Control and Prevention,
World Health Organisation, European Commission for
Public Health, Review on Antimicrobial Resistance.
The modified PICO inclusion/exclusion criteria (Table 1)
were utilised to screen title/abstracts and subsequently
full-texts [27].
Data extraction and quality assessment
Data were extracted from each study into a Data Extrac-
tion Table using Microsoft Excel. The following variables
were collected as part of this process; study identifier, per-
spective, infection of interest (exposure, non-exposure,
case and control definitions), outcome, country setting,
study population, study design, data setting, epidemio-
logical scope, method, sample size, (resistance-related) re-
sult, stated limitations and quality (risk of bias).
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To establish what perspectives and resulting methodolo-
gies have been used in establishing AMR burden, study
perspectives were grouped into either patient, healthcare
system (representing payer and/or provider perspectives)
or economic/societal burden. Studies estimating the sec-
ondary effects of AMR can do so by estimating the poten-
tial impact on health (such as excess deaths), healthcare
system or economic burden (excess cost), so could be
marked under each of these perspectives. Study method-
ologies were grouped into the following categories; regres-
sion analysis (parametric regression models), survival
analysis (this included semi-parametric Cox proportional
hazard models and non-parametric time to event analysis),
matching, multistate models (including decision trees),
economic models (including total factor or computable
general equilibrium models), stepwise calculations (for
example synthesising evidence from the literature and
applying simple calculations to arrive at an estimate),
significance tests and other (if none of the former cat-
egories applied).
The outcome of particular interest for patient burden
was mortality, using odds ratio (OR) and hazard ratio
(HR) measures. In this review, length of stay (LoS),
alongside monetary cost, was recorded as a healthcare
system burden outcome, as it has been shown that for
healthcare associated infections LoS is a major contrib-
uting factor to hospital costs [28]. For economic burden,
monetary cost was considered the main outcome of
interest, however reporting of productivity, GDP and
other such economic measures were also recorded. Im-
pact significance was defined by p values (less than 0.05)
and 95% confidence intervals (CIs), where appropriate.
Risk of bias within individual studies was assessed using
the Newcastle-Ottawa scales for cohort and case-control
studies [29]. For this review a case-control study was de-
fined when outcomes of interest (such death) were used to
select the case and control groups, whereas cohort studies
selected cases based on exposure to resistance [30]. The
Newcastle-Ottawa checklists include four domains of qual-
ity and eight possible stars [29]. The Philips checklist was
used for modelling studies, which includes three do-
mains of quality and 57 possible stars [31]. A quality
score was derived as the proportion of applicable
checklist stars achieved (zero and one representing no
checklist items achieved and all checklist items
achieved respectively), please see Additional file 1: Ta-
bles S1, S2 and S3 for the full checklists utilised.
Risk of bias across the evidence was presented using
the median and interquartile ranges of the quality score
by perspective. This was a deviation in methodology
from the published protocol, which proposed evaluating
sign and significance of results [25], and was chosen as
any other summary figures would be flawed due to the high
heterogeneity in infection of interest and outcome [32].
Data analysis
Due to study heterogeneity no meta-analyses were
performed. Monetary costs found were converted into
2013 United States dollars (USD) by inflating the cost
to 2013 original-currency estimates using annual in-
flation rates [33, 34], then converting this into USD
utilising 2013 average exchange rates [35].
Descriptive statistics (such as proportions of papers
and average quality scores), tables and graphs to collate
and present ORs, HRs, LoS and monetary cost were exe-
cuted in Microsoft Excel and R version 3.3.2 using pack-
ages ‘plyr’, ‘metafor’ and ‘ggplot2’ [36–38].
Results
A total of 5187 unique titles and abstracts were retrieved
over the specified search period. Applying the selection
process resulted in a total of 214 studies being included
in the final review (Fig. 1). One hundred eighty-seven
studies included a patient burden measure, 75 a
Table 1 Inclusion/Exclusion Criteria Applied [25]
Criteria Inclusion Exclusion
Population Humans Animals only
All ages Plants only
All sexes
Infection with antimicrobial
resistant organism (or similar
such as Extended Spectrum
Beta-lactamase producing
organisms). This includes future
predictions of related infected
populations, such as in the
case of a “post-antibiotic” era
Outcomes Associated health burden,
including mortality and
morbidity
Health-Related Quality
of Life only
Associated healthcare cost
burden, including resource
use and opportunity cost
Molecular biology only
Economic burden, including
loss of productivity
Epidemiology only
Burden from not being able
to use antibiotics in ways
previously or currently used in
healthcare, including reduced
surgery or chemotherapy
Outcomes associated with
the evaluation of an
intervention only
Study
design
Case–control studies Editorials
Cohort studies Letters
Cross–sectional studies Case series reports
Longitudinal studies Conference reports
Randomised controlled trials Evaluations of
interventions
Modelling studies Reviews
Economic Evaluations
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healthcare system burden measure, and only 11 studies
included an economic burden measure (Table 2). The
most individually studied genus was Staphylococcus
(23%, 50/214), followed by Klebsiella (9%, 19/214) and
Acinetobacter (8%, 18/214) respectively. The countries
which individually produced the highest number of
studies were the USA (19%, 40/214), followed by
South Korea (7%, 15/214) and Spain (6%, 13/214).
64% of studies (138/214) used data from just one
centre. The majority of studies (89%, 190/214) did
not specify the epidemiological scope in estimating
AMR burden, for example by stating whether relevant
included infections were due to endemic- or outbreak-
related microbes. See Additional file 1: Table S4 for indi-
vidual study details.
Estimating the patient burden of AMR
For estimating the patient burden of AMR, regression
analyses and significance tests were the most utilised
methods (Table 2). 95% (177/187) of studies estimating
patient burden calculated mortality burden, with the
remaining 5% (10/187) focusing on morbidity burden.
Of those estimating a mortality burden, 48% (85/177)
of studies found that AMR had a significant impact
on mortality. Studies which aimed to estimate the im-
pact of resistance on morbidity mainly focused on
Fig. 1 PRISMA Diagram of Article Retrieval & Inclusion
Table 2 Perspectives & Methods used to Estimate the Burden of Antimicrobial Resistance
Patient %
(n = 187)
Healthcare System %
(n = 75)
Economic %
(n = 11)
Regression Analysis 44.9% 34.7% 9.1%
Survival Analysis 20.9% 9.3% 0.0%
Matching 4.8% 10.7% 9.1%
Multistate model 2.1% 6.7% 27.3%
Economic Model 0.0% 0.0% 18.2%
Significance Tests 26.2% 32.0% 0.0%
Stepwise calculation 1.1% 6.7% 27.3%
Qualitative 0.0% 0.0% 9.1%
Note that some studies included more than one burden perspective per study (for example a study reporting impact on mortality and costs would
appear in multiple perspective categories)
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clinical outcomes such as clinical failure, time to
stability, recurring infections or development of sec-
ondary infections [39–47].
The majority of studies that utilised standard regres-
sion techniques to estimate ORs of a mortality event
found resistance to be associated with higher mortality
(Fig. 2a and Fig. 2b). Focusing on those which directly
compared resistant and susceptible infections explicitly,
50% (7/14) and 47% (9/19) of the studies for Gram-
positive and Gram-negative exposures, respectively, had
95% confidence intervals which crossed this OR = 1
threshold. This suggests non-statistical significance of
such results. Across Gram-positive and Gram-negative
infections, this occurred in 4/15 studies investigating re-
sistant cases against “non-exposed” controls and in 2/8
studies investigating the burden of additional resistance
mechanisms on already resistant infections (for example
the impact of vancomycin resistance on Methicillin re-
sistant Staphylococcus aureus (MRSA) patients).
Comparing Figs. 2 and 3 would suggest there is no clear
consensus from either method (parametric regression or
Cox proportional hazards regression) as to whether there is
a significant impact of bacterial resistance mechanisms on
mortality outcomes, though it should be noted that
different measures of mortality have been used across these
studies (see Additional file 1: Table S4). 32% (8/25) of these
studies estimating mortality-related hazard ratios, did so in
relation to in-hospital mortality. Such analysis may not
accurately estimate the impact of exposure (versus non-
exposure) on outcome, due to the failure of the non-
informative censoring assumption, as the cause of being
discharged may be related to the likelihood of experien-
cing death. As the infection type, resistance type and
outcomes are different across the aforementioned studies
a rigorous comparison cannot be made.
Only one study estimated the potential patient burden
of AMR via secondary effects (secondary patient burden),
by evaluating the impact on mortality (excess deaths) of
reduced prophylactic antibiotic efficacy in the United
States [12]. Utilising an evidence synthesis and stepwise
calculation approach, this study estimated that a 30% re-
duction in the efficacy of antibiotic prophylaxis for certain
surgical and chemotherapeutic procedures would result in
6300 infection-related deaths annually [12].
Estimating the healthcare system burden of AMR
For estimating the healthcare system burden (which incor-
porates the payer and provider perspectives) of AMR, re-
gression analyses and significance tests were the most
utilised methods. Seventy-five studies estimated healthcare
system burden, 64 of these estimated LoS burden due to
AMR and 31 estimated monetary cost (with some studies
estimating both). The majority of studies evaluating LoS
(69%, 44/64) found that resistance had a statistically
significant impact, however 39% (17/44) of these utilised
significance testing against descriptive statistics (such as
median length of stay). Thirteen studies estimated excess
LoS due to resistant infections (Fig. 4), with 3 studies using
a multistate modelling methodology to estimate LoS. Multi-
state models attempt to adjust for time dependency
bias [48–50], however this bias has also been adjusted
for in other ways, such as shifting forward the index
date from the date of hospital admission to the first day of
the second calendar month of the patient’s stay [51]. The
majority of excess LoS estimates were for Gram-positive
bacteria, with only two estimates for a Gram-negative bac-
teria (Fig. 4). Excess LoS was estimated at 12.8 days for
MRSA bloodstream infections [95% CI 6.2 - 26.1 days] [48]
in Australia, 11.5 [95% CI: 7.9-15] days for MRSA in
Switzerland [49] and 11.43 [95% CI; 10.44 – 12.43] days for
MRSA in American Veterans, utilising time dependency
adjusted methods described above [50]. These are similar
to those computed by regression but much higher than that
estimated by stepwise calculations (Fig. 4), though all are
from different populations.
A variety of methods have been used to calculate
healthcare system monetary costs, with no clear majority
of one method seen (Table 3). After conversion to 2013
USD for comparing excess/attributable costs, for
Extended-Spectrum beta-Lactamase (ESBL) in blood-
stream infections, a matching study found no significant
impact on healthcare system costs [52], whilst a multi-
state model found an associated $10,154 loss per case
[49]. For MRSA estimates ranged from non-significance
[53] to $28,553 per case [51] (across different popula-
tions for different infections, Table 3).
Estimating the economic burden of AMR
From the economic perspective stepwise calculations,
multistate modelling and economic models were com-
monly used (Table 2). Only a small number of studies
were found in this perspective category, with 11 studies
assessing the burden to the economy resulting from
AMR. Eight of these reported an estimate for the monet-
ary impact of resistance (Table 4). In addition, two stud-
ies found investigated the potential psycho-social impact
of having multi-drug resistant Tuberculosis, concluding
that many patients in the qualitative study felt that
multi-drug resistant Tuberculosis increased stigma and
social isolation [54], and increased the odds of incurring
catastrophic costs (in which [OR = 1.61 (95% CI = 0.98–
2.64), p < 0.06]) [43]. A report from ‘The Review on
Antimicrobial Resistance’ did mention the secondary ef-
fects of AMR from the economic perspective, however
did not attempt to quantify an exact figure for this, in-
stead stating that some proportion of the 120 trillion
USD gained from caesareans, joint operations, chemo-
therapy and organ transplants could be lost [1].
Naylor et al. Antimicrobial Resistance and Infection Control  (2018) 7:58 Page 5 of 17
Fig. 2 Odds ratios of Mortality Outcomes for Resistant Infections. Results presented are from studies utilising regression techniques, where 1.0 represents
the point at which exposure does not affect the odds of the outcome occurring. The box point represents the reported OR value, with horizontal lines
representing the reported 95% Confidence Interval. Results have not been adjusted or adapted to represent sample size, and are presented grouped by
genera. a Gram-positive Bacteria. b Gram-negative Bacteria. [16, 56, 59, 61–103]
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The only studies explicitly estimating the economic
burden of AMR to include Gram-negative infections
were those commissioned by ‘The Review on Antimicro-
bial Resistance’ (in which Escherichia coli and Klebsiella
pnuemoniae were two out of six studied microbes)
[1, 15, 55]. These modelling studies, which utilised eco-
nomic modelling techniques, provided the largest estimates
of cost (though of six resistant microbes), estimating over
Fig. 3 Hazard Ratios of Mortality Outcomes for Resistant Infections. Results presented are from studies utilising Cox proportional hazards
regression techniques, where 1.0 represents the point at which exposure and control experience the same event rate at any point in time.
The box point represents the reported HR value, with horizontal lines representing the reported 95% Confidence Interval. Results have not
been adjusted or adapted to represent sample size, and are presented grouped by genera. a Gram-positive Bacteria. b Gram-negative
Bacteria. [48, 91, 104–121]
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$14 billion to over $3 trillion (2013 USD) in loss to global
GDP by 2050 [15, 55]. Whilst the studies which utilised
multistate modelling techniques (including decision tree
analysis) or stepwise calculations, estimated national costs
for a specific resistance type to range from over $20,000
per MRSA bloodstream infection case to over $7 billion
per year attributable to community acquired MRSA in the
United States (Table 4) [56, 57].
Quality of included studies
For the outcomes and exposures tested relevant to
this review, 199 studies were considered cohort, 1
case-control and 13 modelling studies, whereby the
stated quality checklists were then applied. One add-
itional study was a survey-based qualitative study
and was not quality assessed [54]. Median quality
scores (with interquartile range (IQR)) for health,
healthcare system and economic burden studies were
0.67 (0.56-0.67), 0.56 (0.46-0.67) and 0.53 (0.44-0.60)
respectively. Within all perspectives, quality rarely
exceeded 0.75. Notably there was a lack of economic
burden studies and their median quality score was
lower than that of the health and healthcare system
studies (Fig. 5).
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Table 3 Excess Healthcare system Cost Estimates of Antimicrobial Resistance
Study Exposure Group Control Group Country Method Excess Cost
Estimate
(2013 USD)
Cost per case
[109] CRAB in Columbia Carbapenem susceptible A.
baumannii
Columbia Regression 4,583a
[124] ESBL+ E. coli & Klebsiella species UTI ESBL- E. coli & Klebsiella species UTI USA Significance
Tests
3,237a
[125] ESBL+ E.coli BSI ESBL- E.coli BSI Germany Matching -2081
[49] ESBL+ Enterobacteriaceae BSI ESBL- Enterobacteriaceae BSI Switzerland Multistate
model
10,154
[45] ESBL+ UTI ESBL- UTI Spain Matching &
Regression
3146†
[126] ESBL+ and/or beta-lactamases resistant
UTI
Susceptible UTI Turkey Significance
Tests
90a
[126] Ciprofloxacin resistant UTI Ciprofloxacin susceptible UTI Turkey Significance
Tests
114a
[127] MDR A. baumannii BSI Susceptible A. baumannii BSI Turkey Significance
Tests
15,365
[58] MRSA Non-exposure inpatients Germany Stepwise
Calculations
11,878
[53] MRSA breast abscess MSSA breast abscess USA Matching 515
[128] MRSA BSI Non-exposure BSI South Korea Stepwise
Calculations
5216
[129] MRSA BSI (survivors) Non-nosocomial-infected patients South Korea Matching 11,627
[129] MRSA BSI (non-survivors) Non-nosocomial-infected patients South Korea Matching 15,254
[51] MRSA infections Non-exposure inpatients USA Matching 28,553a
[130] MRSA colonisation & infection Non-exposure inpatients USA Matching 12,167a
[131] Resistant BSI Susceptible BSI India Significance
Tests
912a
[132] Carbapenem-resistant device associated
healthcare acquired infections ICU patients
Non-“device associated healthcare
acquired infections” ICU patients
Greece Significance
Tests
3,884a
[133] VRE colonisation & infections Non-exposure inpatients Canada Matching &
Regression
18,631a
[76] VRE BSI VSE BSI Australia Matching &
Regression
30,093a
[134] VRE BSI in allo-HSCT recipients Non-exposure in allo-HSCT
recipients
USA Significance
Tests
6104
[135] MDR TB Non-MDR TB Germany Stepwise
Calculations
86,321
[136] MDR TB Non-MDR TB South Africa Stepwise
Calculations
6728
[137] MDR TB Non-MDR TB Latvia Regression 33291a
[138] XDR and pre-XDR TB Rifampicin-mono-resistant or MDR TB South Africa Stepwise
Calculations
15,567
[136] XDR TB Non-“XDR or MDR” TB South Africa Stepwise
Calculations
26,989
[139] VRE BSI in leukaemia patients Non-exposure leukaemia patients USA Matching 88150a
Per-patient per-day
[50] MRSA in Switzerland Non-exposure inpatients Switzerland Multistate
model
867
[140] Resistant Gram-negative Bacilli infection Susceptible Gram-negative Bacilli
infection
Singapore Matching 812
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The Newcastle-Ottawa checklist criteria showed that
only 54% of the total available points for adjustment/
comparability of different exposure groups across all
cohort studies were awarded (in all 199 studies, where
two points were available per study [29]), suggesting a
need for more robust analyses estimating the impact of
AMR. Some of the least fulfilled quality assessment cat-
egories by studies were those that focused on represen-
tativeness of the sample utilised (18% of the appraised
studies met this criteria), description/adequacy of
follow-up or non-response rates (40% met this criteria)
and demonstration of non-exposure before study period
(8% met this criteria), across the Newcastle-Ottawa co-
hort quality assessment checklist (199 studies).
For the 13 studies for which the Philips checklist was
utilised to assess quality, there were many indicators for
which scores were generally low, including those related
to descriptions of the choice of model structure and the
approach to obtaining parameter values (less than 1/3 of
studies obtaining the related criteria). However, of note,
none of the relevant studies met the following criteria;
“Have the four principal types of uncertainty been
addressed?”, “If not, has the omission been justified?”
and “Is there evidence that the mathematical logic of the
Table 3 Excess Healthcare system Cost Estimates of Antimicrobial Resistance (Continued)
Study Exposure Group Control Group Country Method Excess Cost
Estimate
(2013 USD)
Annual cost per stated country or stated region
[57] MRSA No-MRSA USA Multistate
model
1,382,733,079
[141] Resistant Streptococcus pneumonia Susceptible Streptococcus
pneumonia
USA Multistate
model
91,773,500
[142] Artemisinin resistant malaria No-“Artemisinin resistant malaria” High endemicity
region
Multistate
model
32,000,000
aStatistically significant where p-value is less than 0.05
Table 4 Excess Economic Burden Estimates of Antimicrobial Resistance
Study Exposure Group Control Group Country Method Excess Cost Estimate (2013 USD)
Cost per case
[135] MDR TB Susceptible TB Germany Stepwise
Calculation
110,063
[135] XDR TB Susceptible TB Germany Stepwise
Calculation
145,679
[143] MDR TB Susceptible TB Europe Stepwise
Calculation
62,931
[143]) XDR TB Susceptible TB Europe Stepwise
Calculation
215,038
[56] MRSA BSI Non-nosocomial-infected
patients
South
Korea
Matching 21,832
Annual cost per stated country or stated region
[141] Resistant Streptococcus
pneumonia
Susceptible Streptococcus
pneumonia
USA Multistate model 236,495,000
[57] MRSA No MRSA USA Multistate model 7,848,223,600
[142] Artemisinin resistant malaria No resistance High
endemicity
regions
Decision Tree 385,000,000
Global economic cost
[15] Resistance globally (doubling of
current infection rates and 100%
resistance)
Lower rates of resistance
(a 40% resistance increase
from current rates)
Global Total Factor
Productivity
model
14,228,000,000 less GDP produced in
2050 compared to 2050 in a scenario
with lower resistance
[55] Resistance globally
(100% resistance rate)
No resistance Global Computable
General
Equilibrium
model
3,158,862,360 less GDP produced in 2050
compared to 2050 with no resistance
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model has been tested thoroughly before use?” [31].
Additionally, only 23% of studies used a lifetime horizon
or justified why they didn’t use it and only 15% demon-
strated a systematic approach to parameter selection.
Box 1: Across Perspectives: ATuberculosis Case Study
To illustrate the importance of clarifying the perspective chosen when
investigating the burden of AMR, the case of multidrug resistant (MDR-) and
extensively drug resistant (XDR-) Tuberculosis (TB) will be used, as studies of
this infection-type provided cost estimates (monetary costs are 2013 USD)
across perspectives (for full study details refer to Additional file 1: Table S4).
Patient burden: In Peruvian adult patients, it was estimated that MDR-
TB was significantly associated with mortality [HR = 7.5 (95% CI; 4.1 – 13.4)]
(Continued)
using regional network data [144]. Likewise, in American patients, using
data from a national institute, XDR was found to be significantly associated
with mortality [HR = 2.8 (95% CI; 1.4 – 5.4)] [145]. In South African adult
patients from one hospital, both MDR and XDR were associated with in-
creased mortality [MDR HR = 3.37, p < 0.0001, and XDR HR = 6.75, p < 0.001]
[146]. All of the aforementioned studies looking into TB and mortality
utilised a Cox proportional hazards approach. Another study utilised a
Kaplan-Meier survival analysis methodology, and found that capromycin
resistance in XDR TB was not significantly associated with mortality
(p < 0.0573) [147]. Using Israeli patient data from a national registry, MDR
was found to be significantly associated with TB-related death [OR =
2.83(95% CI; 1.70-4.72), p < 0.001], using a logistic regression approach [148].
Healthcare system burden: MDR-TB was estimated to cost the South
African healthcare system $6728 excess per case, $33,291 total per case
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(Continued)
in Latvia and $86,321 total per case in Germany using an evidence syn-
thesis approach [135–137]. These studies included factors such as length
of stay, drug costs and services consumed (varying between studies).
Economic burden: It was estimated, by evidence synthesis and
stepwise calculation, that the total economic and societal burden costs
per case for the original EU-15 states (i.e. healthcare system costs plus
productivity loss, compared to susceptible TB) from MDR and XDR TB were
$62,931 and $215,038 [143]. MDR-TB was also found to be independently
associated with incurring catastrophic costs in Peruvian patients older than
15 years [OR = 1.61 (95% CI = 0.98–2.64)], whereby catastrophic costs
were defined as total costs greater than or equal to 20% of house-
hold annual income. Costs included direct medical and non-medical
out-of-pocket costs (such as excess transport and food) [43].
Discussion
The first aim of this review was to establish what
perspectives and resulting methodologies have been
used to estimate AMR burden in recent literature and to
discern the impact this has on the actual estimates of
burden. This review found that out of the 214 studies
included, 187 studies provided an estimate of burden
from the health perspective, 75 studies from the
healthcare system perspective and 11 studies from the
economic perspective. This review describes the large
range of estimates that fall within these categories, and
the methodologies used to obtain them. The most
utilised methodologies were regression analysis for
patient health and healthcare system burden calculations
and either stepwise calculations or multistate models for
economic burden estimates. An additional aim of this
paper was to assess the quality of evidence for health,
healthcare system and economic burden. There was a
lack of economic burden studies, with the median
quality score of these studies being lower than those of
the health and healthcare system studies.
AMR is thought to potentially impact patient health
through increasing patient mortality, though only
around 50% of studies found a statistically significant
impact when comparing resistant and susceptible
infections. A substantial proportion of studies which
used parametric regression or Cox proportional hazards
techniques to estimate the impact of resistant infections
in Gram-negative bacteria on mortality through OR or
HR measures, had high uncertainty.
Evidence on additional length of hospital stay, a key
driver of cost of infections in hospitals, was variable in
terms of methodological choice and values found. A large
proportion of the studies addressing length of stay in a
healthcare facility did not explicitly state excess or
associated length of stay, but rather estimated average
length of stay for different groups and performed univariate
comparisons of these averages. For those that did estimate
excess length of stay, it was expected (given previous
literature [28]) that multistate model length of stay
estimates compared to those found using alternative
methods would be more conservative. However, this review
found that multistate model estimates for length of stay for
MRSA infection and MRSA bloodstream infection were
higher than those using stepwise analysis and regression
analysis [48, 50, 58, 59]. This is likely due to the fact that
the described studies were set in different countries
(Australia, Germany, Switzerland and US) and were mainly
single centre studies, and so less externally valid. The use of
multistate modelling methods to estimate attributable
health and cost burden for resistant infections has
previously been recommended because standard regression
techniques may overstate the attributable length of stay for
hospital onset infections, thus overestimating burden of
AMR [28, 60]. However, we demonstrate that very few
studies took advantage of this method over the search
period.
Due to the small sample of economic burden studies,
no consensus on method can be stated for estimating
the economic burden, though 6 out of the 11 studies did
utilise evidence synthesis and stepwise approaches or
multistate models. The median quality of studies
quantifying the economic burden of AMR fell below
those of health and healthcare system burden studies,
seemingly mainly due to a lack of rigorous, transparent
modelling studies which appropriately present or
incorporate uncertainty.
The recent reports produced by the ‘The Review
on Antimicrobial Resistance’ attempted to address
the lack of economic burden estimates in the field of
AMR [1, 15, 55]. However due to the large scope of
these projects the models used provide only broad,
general estimates (such as the global economic
burden of AMR in general) which may be unsuitable
for cost-effectiveness or resource allocation models. The
review itself calls for the estimates to be developed using
more data-driven approaches [1]. This type of analysis has
also recently been called into question due to its lack of
scientific scrutiny and transparency, questioning the
methodology used [7].
Based on the results of this study, focusing on the
results of the quality assessment of included studies, the
following actions are recommended for future research
in AMR burden;
1. Utilise data from a representative sample of the
population of interest. If this is not achievable
due to data limitations, create and publish a
clearly defined protocol that can be utilised in
other institutions. This will enable future meta-
analyses to be conducted.
2. Choose an appropriate methodology that takes
into account potential confounding factors (such
as patient comorbidities or age) and biases (such
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as time dependency bias, competing risks or non-
informative censoring).
3. Describe data collection, data cleaning, follow-up,
response rates and/or censoring clearly, where
appropriate.
4. Estimate healthcare system and economic impact
where possible.
5. If performing a mathematical or economic model,
clearly describe the reasons for the chosen model
structure (for example by detailing a formal
health economic reasoning, including for chosen
time horizon) and methods of parameterisation
(with structured or systematic methods preferred).
In addition, it is important to discuss how
methodological, structural, heterogeneity and
parameter uncertainty has been addressed
(or discuss why these were not addressed).
Smith and Coast reported that estimates ranged from
less than $15 to around $50,000 for additional costs per
patient per episode to about $20 billion per year from
the societal/economic perspective (converted to 2013
USD) [8]. This review found the healthcare system
excess costs ranged from just almost non-significance to
over $90 million per year, whilst economic costs ranged
from just over $100,000 per case to over $3 trillion total
GDP loss by 2050 (in 2013 USD). Adding to the 21 stud-
ies included in the Smith and Coast 2012 review, this re-
view discusses the results from an additional 214
studies. This review encountered a similar result to that
of Smith and Coast in terms of lack of indirect burden
evidence [8]. However this review did find additional
evidence on the potential secondary effects of AMR,
with studies estimating the potential secondary effect of
AMR on health and economic burden [1, 12].
Strengths of this review include its rigorous systematic
methodology and its use of accepted quality assessment
scales to present the first systematic picture of the
quality of recent AMR burden estimates. This is
particularly important when establishing the current
evidence, as previously published review studies in this
area have either been commentary pieces or have not
incorporated any quality assessment across all three
perspectives [8, 9, 18]. One limitation of this study is
that is has a relatively short search time period. This was
chosen to build upon rather than duplicate the evidence
produced within a previous review, and to capture recent
evidence [8]. Other limitations of the review include that
the Health Related Quality of Life was not included as an
outcome of interest. This was beyond the scope of this
review given the very different methodologies applied in
order to estimate Health Related Quality of Life burden,
and that the majority of discussion of patient burden
currently surrounds mortality impact.
Conclusion
This study concludes that perspective affects chosen
methodology and outcome for quantifying the burden of
AMR. The review finds substantially more research in
patient burden and seemingly more of a consensus on
the most appropriate methods to use (regression or
survival techniques), in comparison to healthcare system
and economic burden research. However, across patient
and healthcare system burden studies, a worryingly high
number of studies are utilising univariate statistical
significance tests, suggesting that a high proportion of
this evidence is unreliable. The review also concludes
that the evidence on the economic burden of AMR is
not substantial, whereby the majority of studies have not
used established health economic modelling techniques
or adhered well to the Philip’s checklist [31]. More
evidence on the secondary effect of AMR on health,
healthcare system and economic burden is also needed
[1, 12].
The estimates presented in this review can be used as
parameter inputs in future health economics models
used to inform health policy, whilst the description of
previous methods used can inform future researchers’
methodology choice (based on their desired perspective).
The review also highlights key areas where research is
needed, including multivariate, internally and externally
valid health and healthcare system burden studies. This
research is needed particularly for Gram-negative bac-
teria. Additionally, high quality economic burden and
secondary burden research is needed in general. Future
AMR burden research should follow the recommenda-
tions highlighted in this review, in order to increase the
quality of evidence available.
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